journal cover

Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine

Research : a Science Partner Journal

May 19, 2019

Dante J Marciani

Get paper from

Abstract

The apparently near-term effects of the monoclonal antibody BAN2401 in slowing the progression of prodromal Alzheimer's disease (AD) has created cautious optimism about the therapeutic use of antibodies that neutralize cytotoxic soluble amyloid-β aggregates, rather than removing plaque....read more

Mentioned in this Paper

Alzheimer's Disease
Amyloid
Analgesics, Anti-Inflammatory
Monoclonal Antibodies
Antigens
Dendritic Cells
Inflammation
Pleomorphism
Vaccines
Cytokine
2
2
11
Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Similar Papers Found In These Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a chronic neurodegenerative disease. This feed focuses on the underlying role of Tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's.

Tauopathies

Tauopathies are neurodegenerative disorders caused due to misfolding and aggregation of the tau protein in neurofibrillary tangles in the brain. Discover the latest research on tauopathies here.

Tau Aggregation: Genomics

Tau Aggregation is an important characteristic in some neurodegenerative disorders, including Alzheimer’s Disease. Discover the latest research using genomics to understand Tau Aggregation.

Tau Antibody Therapy in Neurodegenerative Diseases

Tau vaccination and administration of anti-tau antibodies can prevent pathology and cognitive impairment in transgenic mouse models of tauopathy, suggesting that therapies which increase anti-tau antibodies might slow the development and/or progression of tauopathies including Alzheimer's disease. Here is the latest research.

Neutralizing Antibodies

Neutralizing antibodies bind to their target an impair the biological activity of the target, rather than simply flagging the target for host leukocytes. This is an approach that is being used in vaccine development. Find the latest research on neutralizing antibodies here.

Dementia & Neurodegenerative Diseases

This feed focuses on the impact of insulin resistance, caloric restriction, cytokine singling, and metabolism on dementia and neurodegenerative diseases. Here is the latest research in this domain.

© 2019 Meta ULC. All rights reserved

Promising Results from Alzheimer's Disease Passive Immunotherapy Support the Development of a Preventive Vaccine

Research : a Science Partner Journal

May 19, 2019

Dante J Marciani

PMID: 31549066

DOI: 10.34133/2019/5341375

Abstract

The apparently near-term effects of the monoclonal antibody BAN2401 in slowing the progression of prodromal Alzheimer's disease (AD) has created cautious optimism about the therapeutic use of antibodies that neutralize cytotoxic soluble amyloid-β aggregates, rather than removing plaque....read more

Mentioned in this Paper

Alzheimer's Disease
Amyloid
Analgesics, Anti-Inflammatory
Monoclonal Antibodies
Antigens
2
2
11

Similar Papers Found In These Feeds

Paper Details
References
  • References
  • Citations
  • finger pointing at paper

    References currently unavailable

    We're still populating references for this paper, please check back later.
  • References
  • Citations
  • quote and clock

    No citations available

    This paper may not have been cited yet.

Get paper from

/papers/promising-results-from-alzheimers-disease-passive/31549066